Formycon AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| FYB.DE | 6IB.F | 688382.SS | ROIV | SMZ1.F | 1530.HK | |
|---|---|---|---|---|---|---|
| Market cap | — | 16.34B | 8.77B | 26.36B | 10.15B | 34.82B |
| P/E (TTM) | — | 117.1 | — | — | 28.5 | 4.0 |
| Forward P/E | 17.1 | — | -45.8 | -21.2 | — | 10.3 |
| Price/book | 0.9 | 5.9 | 6.2 | 6.2 | 2.3 | 1.1 |
| Dividend yield | — | — | — | — | 2.64% | 1.83% |
| 1-year change | −15.32% | −1.62% | −46.48% | +105.54% | −27.04% | −51.29% |
| Today | −2.56% | +2.42% | +5.22% | −2.56% | +3.45% | +3.15% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All FYB.DE news ›FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
FDA has accepted for review the biologics license application for FYB206, a proposed pembrolizumab biosimilar developed without a comparative phase 3 efficacy trial. A decision could come in the third quarter of 2027. “Acceptance of the…
Zydus and Formycon Advance FYB206 Keytruda Biosimilar in the US
SMEStreet "Zydus Lifesciences Limited (Zydus), an innovation-led global life-sciences company, and Formycon AG (Formycon), an independent developer of biosimilars, today jointly announced that the US Food and Drug Administration (USFDA)…
Formycon jumps higher - FDA accepts application
The prospect of approval for a Formycon drug to treat cancer sent the company's shares higher on Tuesday. Rising as much as 13 percent to €22, shares of the former SDax-listed company and... Biotechnology & Medical Research Formycon…
Germany's Formycon First to Enter FDA Review for Biosimilar of $31.5 Billion Keytruda
Germany's Formycon has become the first company to enter U.S. FDA review for a biosimilar of Keytruda, the world's top-selling drug, with its candidate FYB206. The company shortened development time by skipping Phase 3 trials, and a…
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA
Zydus Lifesciences Limited and Formycon AG, an independent developer of biosimilars, today jointly announced that the US Food and Drug Administration has accepted for review the Biologics License Application for FYB206, a proposed…
Zydus, Formycon Hit Major USFDA Milestone for First USD 31 Billion Keytruda Biosimilar
New Delhi: Indian pharmaceutical major Zydus Lifesciences Limited and German biosimilar developer Formycon AG have achieved a significant regulatory milestone, jointly announcing that the US Food and Drug Administration (USFDA) has…
Zydus, Formycon Get USFDA Review Acceptance For Keytruda Biosimilar FYB206
Mumbai: Zydus Lifesciences and Formycon AG jointly announced on Monday, 13 October 2026, that the US Food and Drug Administration (USFDA) has accepted for review the Biologics License Application (BLA) for FYB206. FYB206 is a proposed…
Sensex, Nifty Today LIVE: NSE Stock Market Updates, Oct 13, 2026: Suzlon Energy sees unexplained price jump | Zydus, Formycon's FYB206 biosimilar up for USFDA review
Suzlon Energy Limited reports a "Material Price Movement" in its stock, citing no known cause from external sources. Zydus and Formycon's FYB206 biosimilar to Keytruda® accepted for USFDA review, marking a significant step in expanding…
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
Dec 09, 2025, 08:52 ET About Zydus Lifesciences Limited 1) Keytruda® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, (NYSE: MRK) Rahway, NJ/USA. Zydus, MSN partner to Launch First Generic of Adempas®…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
businessupturn.com2
-
medicaldialogues.in2
-
newswire.ca2
-
equitybulls.com1
-
finance.biggo.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.